Protein C ActivatorAlternative Names: PCA
Latest Information Update: 18 Jul 2002
At a glance
- Originator Gilead Sciences
- Class Anticoagulants
- Mechanism of Action Protein C stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 12 Jun 1998 New profile
- 12 Jun 1998 Preclinical development for Thrombosis in USA (Unknown route)